The potential of panobinostat as a treatment option in patients with relapsed and refractory multiple myeloma

Ther Adv Hematol. 2014 Dec;5(6):197-210. doi: 10.1177/2040620714552614.

Abstract

Panobinostat is an investigational and potent histone deacetylase inhibitor (HDACi) that has shown promise as an antimultiple myeloma agent in the preclinical setting. In this review, we discuss the rationale for the use of panobinostat as a combination therapy for multiple myeloma and provide an overview of recent and ongoing clinical trials testing the safety and efficacy of panobinostat for the treatment of the disease.

Keywords: histone deacetylase inhibitor; multiple myeloma; panobinostat.

Publication types

  • Review